What is Rigel?
Founded in 1996, Rigel Pharmaceuticals operates as a specialized biopharmaceutical entity focused on the discovery and development of novel small-molecule drugs. The company's research mandate targets complex medical challenges, including autoimmune diseases, muscle disorders, and various inflammatory conditions. By leveraging a sophisticated R&D infrastructure, Rigel has established a robust market position, transitioning from early-stage research to a mature clinical-stage developer. Its operational model relies on a blend of internal discovery and strategic partnerships, allowing the firm to navigate the high-risk, high-reward landscape of drug development while maintaining a focus on patient-centric outcomes.
How much funding has Rigel raised?
Rigel has raised a total of $888.4M across 12 funding rounds:
Stock Offering
$127.5M
Stock Offering
$101.5M
Stock Offering
$140.5M
Stock Offering
$135.7M
Stock Offering
$46M
Stock Offering
$69.7M
Stock Offering
$58.4M
Debt
$60M
Stock Issuance/Offering (2008): $127.5M backed by Undisclosed
Stock Issuance/Offering (2009): $101.5M with participation from Undisclosed
Stock Issuance/Offering (2011): $140.5M led by Undisclosed
Stock Issuance/Offering (2012): $135.7M supported by Undisclosed
Stock Issuance/Offering (2017): $46M featuring Undisclosed
Stock Issuance/Offering (2017): $69.7M backed by Undisclosed
Stock Issuance/Offering (2018): $58.4M with participation from Undisclosed
Debt (2019): $60M led by MidCap Financial
Key Investors in Rigel
Novartis
Novartis is a global pharmaceutical manufacturer headquartered in Switzerland, specializing in developing and producing innovative medications and healthcare solutions across multiple therapeutic areas.
MPM Capital
MPM BioImpact manages early-stage venture funds and private impact funds, focusing on converting cutting-edge science into life-saving therapeutics.
Alta Partners
Alta Partners is a prominent venture capital firm specializing in healthcare and life sciences, dedicated to supporting entrepreneurs in building impactful companies since 1996.
What's next for Rigel?
Looking ahead, Rigel is positioned to leverage its recent capital influx to accelerate its late-stage clinical trials and expand its therapeutic portfolio. The strategic focus remains on optimizing the commercialization of its existing assets while simultaneously exploring new molecular targets. By maintaining a disciplined approach to capital allocation and fostering high-value institutional partnerships, Rigel aims to solidify its standing as a leader in the biopharma space. The company's trajectory suggests a continued emphasis on scaling its operational capabilities to meet the evolving demands of the global healthcare market, particularly in addressing unmet needs within the immunology and inflammatory disease segments.
See full Rigel company page
